index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
14301,The prospective evaluation of the TB strain typing service in England: a mixed methods study,"BACKGROUND: In response to rising TB notification rates in England, universal strain typing was introduced in 2010. We evaluated the acceptability, effectiveness and cost-effectiveness of the TB strain typing service (TB-STS). METHODS: We conducted a mixed-methods evaluation using routine laboratory, clinic and public health data. We estimated the effect of the TB-STS on detection of false positive Mycobacterium tuberculosis diagnoses (2010-2012); contact tracing yield (number of infections or active disease per pulmonary TB case); and diagnostic delay. We developed a deterministic age-structured compartmental model to explore the effectiveness of the TB-STS, which informed a cost-effectiveness analysis. RESULTS: Semi-structured interviews explored user experience. Strain typing identified 17 additional false positive diagnoses. The TB-STS had no significant effect on contact tracing yield or diagnostic delay. Mathematical modelling suggested increasing the proportion of infections detected would have little value in reducing TB incidence in the white UK-born population. However, in the non-white UK-born and non-UK-born populations, over 20 years, if detection of latent infection increases from 3% to 13% per year, then TB incidence would decrease by 11%; reducing diagnostic delay by one week could lead to 25% reduction in incidence. The current TB-STS was not predicted to be cost-effective over 20 years ( pound95 628/quality-adjusted life-years). Interviews found people had mixed experiences, but identified broader benefits, of the TB-STS. CONCLUSIONS: To reduce costs, improve efficiency and increase effectiveness, we recommend changes to the TB-STS, including discontinuing routine cluster investigations and focusing on reducing diagnostic delay across the TB programme. This evaluation of a complex intervention informs the future of strain typing in the era of rapidly advancing technologies.",2015-01-18278,25882538,Thorax,J Mears,2016,71 / 8,,No,25882538,"J Mears; E Vynnycky; J Lord; M W Borgdorff; T Cohen; D Crisp; J A Innes; M Lilley; H Maguire; T D McHugh; G Woltmann; I Abubakar; P Sonnenberg; The prospective evaluation of the TB strain typing service in England: a mixed methods study, Thorax, 2016 Aug; 71(8):0040-6376",QALY,United Kingdom,Not Stated,Not Stated,Universal tuberculosis strain typing service vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,20 Years,3.50,3.50,95628,United Kingdom,2013,166178.78
14302,Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia,"BACKGROUND: Pneumococcal diseases in children under five years are common and preventable. In Colombia there are two pneumococcal conjugate vaccines (PCV) that have proved clinical efficacy. The aim was to estimate the cost-effectiveness of 13-valent PCV (PCV13) and 10-valent PCV (PCV10) in terms of prevention of Invasive Pneumococcal Diseases (IPD), radiologically-confirmed pneumonia, and their related mortality, as well as, acute otitis media (AOM) in a cohort of newborns in Colombia. METHODS: We developed an analytical decision tree model with national data including the distribution of pneumococcal serotypes in Colombia between 2009 and 2013. A simulation of vaccination of 90% of newborns in Colombia took place with a time horizon of 5 years. The analysis was done from the Colombian health system perspective. Vaccines efficacy parameters were measured as life-years gained (LYG) and avoided morbidity by pneumococcal diseases; they were determined by a systematic review of literature. A health insurance company provided the costs. A probabilistic and a univariate sensitivity analysis for epidemiological, efficacy and cost parameters were done. RESULTS: After 5 years projection, PCV13 would prevent 437 deaths due to pneumococcal infections versus 321 that would be prevented by PCV10, compared to no vaccination. PCV13 would generate 25 396 LYG, and PCV10 would generate 18 708 LYG. Medical costs avoided would be US$ 19 479 395 for PCV13 and US$ 13 703 271 for PCV10. Compared to no vaccination, PCV13 and PCV10 were cost-effective, with an incremental cost-effectiveness ratio (ICER) of US$ 489.26 and US$ 813.41 per additional LYG, respectively; besides, PCV13 was dominant over PCV10 due to lower costs and better outcomes. CONCLUSION: PCV13 is a cost-saving strategy compared with PCV10, as part of a universal coverage vaccination program in Colombian children under one year. PCV13 is expected to lead to a greater decrement in infant mortality from pneumococcal diseases, and a higher cost saving by preventing more pneumococcal diseases compared with PCV10 in a 5 years projection.",2015-01-18297,25878563,Int J Cardiol,Jaime E Ordonez,2015,13 /,6,No,25878563,"Jaime E Ordonez; John Jairo Orozco; Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia, Int J Cardiol, 2015; 13():1874-1754; 6",QALY,Colombia,Not Stated,Not Stated,13-valent pneumococcal conjugate vaccines (PCV13) vs. 10-valent pneumococcal conjugate vaccines (PCV10),Not Stated,4 Years,Not Stated,"Female, Male",Full,5 Years,3.00,3.00,Not Stated,Colombia,2013,Not Stated
14303,Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia,"BACKGROUND: Pneumococcal diseases in children under five years are common and preventable. In Colombia there are two pneumococcal conjugate vaccines (PCV) that have proved clinical efficacy. The aim was to estimate the cost-effectiveness of 13-valent PCV (PCV13) and 10-valent PCV (PCV10) in terms of prevention of Invasive Pneumococcal Diseases (IPD), radiologically-confirmed pneumonia, and their related mortality, as well as, acute otitis media (AOM) in a cohort of newborns in Colombia. METHODS: We developed an analytical decision tree model with national data including the distribution of pneumococcal serotypes in Colombia between 2009 and 2013. A simulation of vaccination of 90% of newborns in Colombia took place with a time horizon of 5 years. The analysis was done from the Colombian health system perspective. Vaccines efficacy parameters were measured as life-years gained (LYG) and avoided morbidity by pneumococcal diseases; they were determined by a systematic review of literature. A health insurance company provided the costs. A probabilistic and a univariate sensitivity analysis for epidemiological, efficacy and cost parameters were done. RESULTS: After 5 years projection, PCV13 would prevent 437 deaths due to pneumococcal infections versus 321 that would be prevented by PCV10, compared to no vaccination. PCV13 would generate 25 396 LYG, and PCV10 would generate 18 708 LYG. Medical costs avoided would be US$ 19 479 395 for PCV13 and US$ 13 703 271 for PCV10. Compared to no vaccination, PCV13 and PCV10 were cost-effective, with an incremental cost-effectiveness ratio (ICER) of US$ 489.26 and US$ 813.41 per additional LYG, respectively; besides, PCV13 was dominant over PCV10 due to lower costs and better outcomes. CONCLUSION: PCV13 is a cost-saving strategy compared with PCV10, as part of a universal coverage vaccination program in Colombian children under one year. PCV13 is expected to lead to a greater decrement in infant mortality from pneumococcal diseases, and a higher cost saving by preventing more pneumococcal diseases compared with PCV10 in a 5 years projection.",2015-01-18297,25878563,Int J Cardiol,Jaime E Ordonez,2015,13 /,6,No,25878563,"Jaime E Ordonez; John Jairo Orozco; Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia, Int J Cardiol, 2015; 13():1874-1754; 6",QALY,Colombia,Not Stated,Not Stated,13-valent pneumococcal conjugate vaccines (PCV13) vs. None,Not Stated,4 Years,Not Stated,"Female, Male",Full,5 Years,3.00,3.00,Not Stated,Colombia,2013,Not Stated
14304,Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia,"BACKGROUND: Pneumococcal diseases in children under five years are common and preventable. In Colombia there are two pneumococcal conjugate vaccines (PCV) that have proved clinical efficacy. The aim was to estimate the cost-effectiveness of 13-valent PCV (PCV13) and 10-valent PCV (PCV10) in terms of prevention of Invasive Pneumococcal Diseases (IPD), radiologically-confirmed pneumonia, and their related mortality, as well as, acute otitis media (AOM) in a cohort of newborns in Colombia. METHODS: We developed an analytical decision tree model with national data including the distribution of pneumococcal serotypes in Colombia between 2009 and 2013. A simulation of vaccination of 90% of newborns in Colombia took place with a time horizon of 5 years. The analysis was done from the Colombian health system perspective. Vaccines efficacy parameters were measured as life-years gained (LYG) and avoided morbidity by pneumococcal diseases; they were determined by a systematic review of literature. A health insurance company provided the costs. A probabilistic and a univariate sensitivity analysis for epidemiological, efficacy and cost parameters were done. RESULTS: After 5 years projection, PCV13 would prevent 437 deaths due to pneumococcal infections versus 321 that would be prevented by PCV10, compared to no vaccination. PCV13 would generate 25 396 LYG, and PCV10 would generate 18 708 LYG. Medical costs avoided would be US$ 19 479 395 for PCV13 and US$ 13 703 271 for PCV10. Compared to no vaccination, PCV13 and PCV10 were cost-effective, with an incremental cost-effectiveness ratio (ICER) of US$ 489.26 and US$ 813.41 per additional LYG, respectively; besides, PCV13 was dominant over PCV10 due to lower costs and better outcomes. CONCLUSION: PCV13 is a cost-saving strategy compared with PCV10, as part of a universal coverage vaccination program in Colombian children under one year. PCV13 is expected to lead to a greater decrement in infant mortality from pneumococcal diseases, and a higher cost saving by preventing more pneumococcal diseases compared with PCV10 in a 5 years projection.",2015-01-18297,25878563,Int J Cardiol,Jaime E Ordonez,2015,13 /,6,No,25878563,"Jaime E Ordonez; John Jairo Orozco; Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia, Int J Cardiol, 2015; 13():1874-1754; 6",QALY,Colombia,Not Stated,Not Stated,10-valent pneumococcal conjugate vaccines (PCV10) vs. None,Not Stated,4 Years,Not Stated,"Female, Male",Full,5 Years,3.00,3.00,Not Stated,Colombia,2013,Not Stated
14305,Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis,"BACKGROUND: A watch and wait (WW) strategy is the standard of care for patients with asymptomatic advanced-stage follicular lymphoma. Recent data have demonstrated an improvement in the time to progression with rituximab induction (RI) with or without rituximab maintenance (RM) in comparison with a WW strategy wait in such patients. It remains unclear whether this is a cost-effective strategy. METHODS: A Markov decision analysis model was developed to compare the clinical outcomes, costs, and cost-effectiveness of RI (4 weekly doses) plus RM (12 doses every 2 months), RI (4 weekly doses), and a WW strategy for patients newly diagnosed with low-burden, asymptomatic advanced-stage follicular lymphoma over a lifetime horizon. Baseline probabilities and utilities were derived from a systematic review of published studies, and they were evaluated on a 6-month cycle. A Canadian public health payer's perspective was adopted, and costs were presented in 2012 Canadian dollars. RESULTS: RI was the cheapest strategy. It was less costly at $59,953 versus $67,489 for the RM arm and $75,895 for the WW arm. It was also associated with a slightly lower quality-adjusted life expectancy at 6.16 quality-adjusted life years (QALYs) versus 6.28 QALYs for the RM strategy but was superior to WW (5.71 QALYs). In sensitivity analyses of key variables, this effectiveness was sensitive to the probability of first and second progression in the RI arm, and this indicated relatively neutral effectiveness between the 2 rituximab arms. CONCLUSIONS: RI without maintenance for asymptomatic advanced-stage follicular lymphoma is the preferred strategy: it minimizes costs per patient over a lifetime horizon.",2015-01-18302,25877511,Cancer,Anca Prica,2015,121 / 15,2637-45,No,25877511,"Anca Prica; Kelvin Chan; Matthew Cheung; Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis, Cancer, 2015 Aug 1; 121(15):0008-543X; 2637-45",QALY,Canada,Not Stated,Not Stated,Rituximab induction + rituximab maintenance strategy vs. rituximab induction,"patients with newly diagnosed, untreated, lowburden, asymptomatic advanced-stage follicular lymphoma.",60 Years,60 Years,"Female, Male",Full,30 Years,5.00,5.00,62360,Canada,2012,70311.79
14306,Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis,"BACKGROUND: A watch and wait (WW) strategy is the standard of care for patients with asymptomatic advanced-stage follicular lymphoma. Recent data have demonstrated an improvement in the time to progression with rituximab induction (RI) with or without rituximab maintenance (RM) in comparison with a WW strategy wait in such patients. It remains unclear whether this is a cost-effective strategy. METHODS: A Markov decision analysis model was developed to compare the clinical outcomes, costs, and cost-effectiveness of RI (4 weekly doses) plus RM (12 doses every 2 months), RI (4 weekly doses), and a WW strategy for patients newly diagnosed with low-burden, asymptomatic advanced-stage follicular lymphoma over a lifetime horizon. Baseline probabilities and utilities were derived from a systematic review of published studies, and they were evaluated on a 6-month cycle. A Canadian public health payer's perspective was adopted, and costs were presented in 2012 Canadian dollars. RESULTS: RI was the cheapest strategy. It was less costly at $59,953 versus $67,489 for the RM arm and $75,895 for the WW arm. It was also associated with a slightly lower quality-adjusted life expectancy at 6.16 quality-adjusted life years (QALYs) versus 6.28 QALYs for the RM strategy but was superior to WW (5.71 QALYs). In sensitivity analyses of key variables, this effectiveness was sensitive to the probability of first and second progression in the RI arm, and this indicated relatively neutral effectiveness between the 2 rituximab arms. CONCLUSIONS: RI without maintenance for asymptomatic advanced-stage follicular lymphoma is the preferred strategy: it minimizes costs per patient over a lifetime horizon.",2015-01-18302,25877511,Cancer,Anca Prica,2015,121 / 15,2637-45,No,25877511,"Anca Prica; Kelvin Chan; Matthew Cheung; Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis, Cancer, 2015 Aug 1; 121(15):0008-543X; 2637-45",QALY,Canada,Not Stated,Not Stated,Rituximab induction strategy vs. Standard/Usual Care- watch and wait strategy,"patients with newly diagnosed, untreated, lowburden, asymptomatic advanced-stage follicular lymphoma.",60 Years,60 Years,"Female, Male",Full,30 Years,5.00,5.00,-35426.67,Canada,2012,-39944.08
14307,Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme,"INTRODUCTION: In January 2013 a novel type of multicomponent protein-based vaccine against group B meningococcal disease was licensed by the European Medicines Agency. With the widespread use of the meningococcal serogroup C conjugate vaccines, serogroup B remains now the major cause of bacterial meningitis and septicaemia in young children in Europe. The aim of this study is to investigate the health and the economic outcomes of MenB vaccine introduction into the Italian routine mass vaccination programme. METHODS: The present work is structured in two main parts. Firstly, we assess the epidemiological burden of group B meningococcal disease using official hospitalisation and notification data from two of the most populated Italian regions (Lombardia and Piemonte) during a 6-year study period (2007-2012). Secondly, we evaluate the cost-effectiveness of the immunisation programme in Italy from the public health payer perspective under base case parameters assumptions and performing a comprehensive sensitivity analysis to assess the robustness and the uncertainty of our model results. RESULTS: MenB serotype is responsible for 59% of the 341 cases of Invasive Meningococcal Disease in Lombardia and Piemonte. Incidence rate for MenB infection is estimated to be 0.21/100,000/y resulting at the highest level in children </=4 years of age. Although the new MenB vaccine can potentially prevent about one third of the disease cases in the Italian population, model results show this strategy is unlikely to be cost-effective (ICER value over euro350,000/QALY) with a vaccine that prevents disease only. These results are robust under most of the sensitivity scenarios except when allowing for lower discount rates. DISCUSSION: The introduction of the novel vaccine into the routine immunisation schedule needs to be carefully evaluated. The new MenB vaccine has the potential to reduce the disease burden at the population level. However, from the Italian Health Service perspective, the immunisation programme is unlikely to be cost-effective at the current incidence levels and vaccine price.",2015-01-18306,25874805,PLoS One,Marcello Tirani,2015,10 / 4,e0123383,No,25874805,"Marcello Tirani; Michela Meregaglia; Alessia Melegaro; Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme, PLoS One , 2015; 10(4):1932-6203; e0123383",QALY,Italy,Not Stated,Not Stated,Bexsero vaccinaiton to prevent group b meningococcal disease vs. None,Born into a susceptible unvaccinated state,18 Years,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,376042,Euro,2013,554864.55
14308,Long-term cost-effectiveness of Oncotype DX versus current clinical practice from a Dutch cost perspective,"INTRODUCTION: This study analyzes the incremental cost-effectiveness of Oncotype DX(R) testing to support adjuvant chemotherapy recommendations, versus current clinical practice, for patients with estrogen receptor-positive (ER+), node-negative or micrometastatic (pN1mic) early-stage breast cancer in The Netherlands. METHODS: Markov model projecting distant recurrence, survival, quality-adjusted life years (QALYs) and healthcare costs over a 30-year time horizon. RESULTS: Oncotype DX was projected to increase QALYs by 0.11 (0.07-0.58) and costs with euro1236 (range: -euro142-euro1236) resulting in an incremental cost-effectiveness ratio of euro11,236/QALY under the most conservative scenario. CONCLUSION: Reallocation of adjuvant chemotherapy based on Oncotype DX testing is most likely a cost-effective use of scarce resources, improving long-term survival and QALYs at marginal or lower costs.",2015-01-18312,25872415,J Comp Eff Res,Michelle Kip,2015,/,1-13,No,25872415,"Michelle Kip; Helma Monteban; Lotte Steuten; Long-term cost-effectiveness of Oncotype DX versus current clinical practice from a Dutch cost perspective, J Comp Eff Res, 2015 Apr 15; ():2042-6313; 1-13",QALY,Netherlands,Not Stated,Not Stated,Oncotype dx testing vs. Standard/Usual Care- Current clinical practice,"estrogen receptor-positive (ER+), node negative",60 Years,60 Years,Female,Full,30 Years,4.00,1.50,11236,Euro,2012,16286.67
14309,Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12,"BACKGROUND: The NCIC CTG LY.12 study showed that gemcitabine, dexamethasone, and cisplatin (GDP) were noninferior to dexamethasone, cytarabine, and cisplatin (DHAP) in patients with relapsed or refractory aggressive histology lymphoma prior to autologous stem cell transplantation. We conducted an economic evaluation from the perspective of the Canadian public healthcare system based on trial data. METHODS: The primary outcome was an incremental cost utility analysis comparing costs and benefits associated with GDP vs DHAP. Resource utilization data were collected from 519 Canadian patients in the trial. Costs were presented in 2012 Canadian dollars and disaggregated to highlight the major cost drivers of care. Benefit was measured as quality-adjusted life-years (QALYs) based on utilities translated from prospectively collected quality-of-life data. All statistical tests were two-sided. RESULTS: The mean overall costs of treatment per patient in the GDP and DHAP arms were $19 961 (95% confidence interval (CI) = $17 286 to $24 565) and $34 425 (95% CI = $31 901 to $39 520), respectively, with an incremental difference in direct medical costs of $14 464 per patient in favor of GDP (P < .001). The predominant cost driver for both treatment arms was related to hospitalizations. The mean discounted quality-adjusted overall survival with GDP was 0.161 QALYs and 0.152 QALYs for DHAP (difference = 0.01 QALYs, P = .146). In probabilistic sensitivity analysis, GDP was associated with both cost savings and improved quality-adjusted outcomes compared with DHAP in 92.6% of cost-pair simulations. CONCLUSIONS: GDP was associated with both lower costs and similar quality-adjusted outcomes compared with DHAP in patients with relapsed or refractory lymphoma. Considering both costs and outcomes, GDP was the dominant therapy.",2015-01-18319,25868579,J Natl Cancer Inst,Matthew C Cheung,2015,107 / 7,,No,25868579,"Matthew C Cheung; Annette E Hay; Michael Crump; Kevin R Imrie; Yuyao Song; Shazia Hassan; Nancy Risebrough; Jonathan Sussman; Stephen Couban; David MacDonald; Vishal Kukreti; C Tom Kouroukis; Tara Baetz; David Szwajcer; Pierre Desjardins; Lois Shepherd; Ralph M Meyer; Al Le; Bingshu E Chen; Nicole Mittmann; Committee on Economic Analysis a; Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12, J Natl Cancer Inst, 2015 Jul; 107(7):0027-8874",QALY,Canada,Not Stated,Not Stated,Gemcitabine/dexamethasone/cisplatin vs. Cytarabine/Dexamethasone/Cisplatin,Not Stated,74 Years,19 Years,"Female, Male",Full,8 Years,Not Stated,5.00,-1607111.13,Canada,2012,-1812040.83
14310,Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording,"AIMS: The aim of this study was to estimate the cost-effectiveness of 2 weeks of intermittent screening for asymptomatic atrial fibrillation (AF) in 75/76-year-old individuals. METHODS AND RESULTS: The cost-effectiveness analysis of screening in 75-year-old individuals was based on a lifelong decision analytic Markov model. In this model, 1000 hypothetical individuals, who matched the population of the STROKESTOP study, were simulated. The population was analysed for different parameters such as prevalence, AF status, treatment with oral anticoagulation, stroke risk, utility, and costs. In the base-case scenario, screening of 1000 individuals resulted in 263 fewer patient-years with undetected AF. This implies eight fewer strokes, 11 more life-years, and 12 more quality-adjusted life years (QALYs) per 1000 screened individuals. The screening implies an incremental cost of euro50 012, resulting in a cost of euro4313 per gained QALY and euro6583 per avoided stroke. CONCLUSIONS: With the use of a decision analytic simulation model, it has been shown that screening for asymptomatic AF in 75/76-year-old individuals is cost-effective.",2015-01-18320,25868469,Europace,Mattias Aronsson,2015,17 / 7,1023-9,No,25868469,"Mattias Aronsson; Emma Svennberg; Marten Rosenqvist; Johan Engdahl; Faris Al-Khalili; Leif Friberg; Viveka Frykman-Kull; Lars-Ake Levin; Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording, Europace, 2015 Jul; 17(7):1099-5129; 1023-9",QALY,Sweden,Not Stated,Not Stated,Hand-held ECG recorder to screen asymptomatic atrial fibrillation vs. None,Not Stated,76 Years,75 Years,"Female, Male",Full,"Lifetime, 50, 15 years",3.00,3.00,4313,Euro,2014,6269.63
14311,A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer,"BACKGROUND: Many western countries have established female human papillomavirus (HPV) vaccination programs for the prevention of cervical cancer. The quadrivalent HPV vaccine (HPV4) has proven efficacy against additional HPV-related disease in both sexes, but the cost effectiveness of male HPV vaccination remains controversial. To assess the cost effectiveness of male HPV vaccination in Canada with respect to oropharyngeal cancer (OPC), the authors performed a preliminary cost-effectiveness analysis. METHODS: After an extensive literature review regarding HPV-related OPC in Canadian males, health care costs and clinical effectiveness estimates were obtained. A Markov model was used to compare the potential costs and effectiveness of HPV4 versus no vaccination among boys aged 12 years. A theoretical cohort based on a Canadian population of 192,940 boys aged 12 years in 2012 was assumed to apply the model. A 3-month cycle length was used with a ""lifetime"" time horizon. The outcome of the analysis was the incremental cost per quality-adjusted life-year (QALY). Sensitivity analyses were conducted on variables, including the vaccine uptake rate and vaccine efficacy. RESULTS: Assuming 99% vaccine efficacy and 70% uptake, HPV4 produced 0.05 more QALYs and saved $145 Canadian dollars (CAD) per individual compared with no vaccine (QALYs and costs were discounted at 5% per year). Assuming 50% vaccine efficacy and 50% uptake, HPV4 produced 0.023 more QALYs and saved $42 CAD. The results indicated that HPV4 in males may potentially save between $8 and $28 million CAD for the theoretical cohort of 192,940 over its lifetime. CONCLUSIONS: On the basis of this model, HPV vaccination for boys aged 12 years may be a cost-effective strategy for the prevention of OPC in Canada.",2015-01-18322,25867018,Cancer,Donna M Graham,2015,121 / 11,1785-92,No,25867018,"Donna M Graham; Wanrudee Isaranuwatchai; Steven Habbous; Claire de Oliveira; Geoffrey Liu; Lillian L Siu; Jeffrey S Hoch; A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer, Cancer, 2015 Jun 1; 121(11):0008-543X; 1785-92",QALY,Canada,Not Stated,Not Stated,Quadrivalent Human Papillomavirus Vaccination vaccine (HPV4) vs. None,"Vaccine efficacy was 83.8% and that the uptake rate was 50%,",12 Years,12 Years,Male,Full,Lifetime,5.00,5.00,-2454.29,Canada,2009,-2606.5
14312,Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation,"There are reports of pretransplant sofosbuvir (SOF) plus ribavirin being effective in preventing recurrent hepatitis C virus (HCV) infection after liver transplantation (LT). The aim of this study was to assess the cost-effectiveness of this strategy in the area served by the North Italy Transplant program. We retrospectively assessed the impact of HCV infection on post-LT survival in 2376 consecutive adult patients (MELD </= 25, unknown genotype, period 2004-2009) and the prevalence costs of conventional standard of care (SOC) antiviral therapy (pegylated interferon plus ribavirin) after LT. A Markov model was developed to compare two strategies: 12-24 weeks of SOF+ ribavirin for pre-LT anti-HCV treatment versus on-demand post-LT SOC antiviral therapy. Among the 1794 patients undergoing LT, 860 (48%) were HCV+ and 50% of them were given SOC therapy after LT (mean cost of drugs and adverse effect management = 14 421euro per patient). HCV etiology had a strong impact on post-LT survival (hazard ratio = 1.59, 95% CI = 1.22-2.09, P = 0.0007). After Monte Carlo simulation, pre-LT SOF therapy showed a median survival benefit of 1.5 quality-adjusted life years and an Incremental cost-effectiveness ratio (ICER) of 30 663euro/QALY, proving cost-effective in our particular Italian scenario. The costs of SOF therapy, sustained viral response rate 12 weeks after LT, and recipient's age were the main ICER predictors at multivariate analysis. This study proposes a dynamic model based on real-life data from northern Italy for adjusting the costs of pre-LT direct-acting antiviral therapies to the actual sustained virological response reached after LT.",2015-01-18326,25865602,Transpl Int,Alessandro Vitale,2015,28 / 9,1055-65,No,25865602,"Alessandro Vitale; Gaya Spolverato; Patrizia Burra; Tullia Maria De Feo; Luca Belli; Francesca Donato; Gianluca Svegliati Baroni; Tania Marianelli; Antonio Picciotto; Pierluigi Toniutto; Sherrie Bhoori; Nicola Passigato; Maria Grazia Luca; Francesco Paolo Russo; Umberto Cillo; Stefano Fagiuoli; Liver Transplantation NITp worki; Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation, Transpl Int, 2015 Sep; 28(9):0934-0874; 1055-65",QALY,Italy,Not Stated,Not Stated,12-24 weeks of pretransplant sofosbuvir (SOF) + ribavirin for pre-liver transplantation anti-hepatitis C virus treatment vs. Standard/Usual Care- On-demand post-liver transplantation standard antiviral therapy,Listed for liver transplantation; having hepatocellular carci- noma; 55 year-old recipient receiving a 56-year-old graft,64 Years,41 Years,"Female, Male",Full,Lifetime,3.00,3.00,30663,Euro,2013,45244.45
14313,Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba to background regimens in Germany,"OBJECTIVE: To assess the cost-effectiveness of adding delamanid (Deltyba) to a background regimen (BR) for treating multidrug-resistant tuberculosis (MDR-TB) in Germany. METHODS: The incremental cost-effectiveness of treating a cohort of MDR-TB patients, 38-years old on average, with Deltyba plus BR versus a five drug- BR regimen alone was compared in a Markov model over a period of 10 years. Cost per quality-adjusted life year (QALY) and disability-adjusted life years (DALY) were determined from a societal perspective. Recent data from a German cost calculation on MDR-TB were applied to the 24-month outcome results of patients participating in the placebo-controlled, phase II Otsuka's Trial 204. Costs and effectiveness were discounted at a rate of 3% and subjected to deterministic as well as probabilistic sensitivity analysis in a Monte Carlo simulation. RESULTS: Based on the current market prices the total discounted cost per patient on BR plus Deltyba was euro142,732 compared to euro150,909 for BR alone. The total discounted QALYs per patient were 8.47 for Deltyba versus 6.13 for BR alone. Accordingly, the addition of Deltyba proved to be dominant over the BR alone-strategy by simultaneously saving euro8177 and gaining 2.34 QALYs. Deltyba was cost saving in 73% of probabilistic sensitivity analyses compared to BR alone and 100% cost effective at a willingness-to-pay (WTP) threshold of euro10,000. CONCLUSIONS: Under conditions prevalent in Germany, Deltyba added to a five drug BR regimen is likely to be cost-saving compared to BR alone under a wide range of assumptions. Adding delamanid remained cost-effective when costs due to loss of productivity were excluded as the QALYs gained by lower lethality and a higher proportion of successfully treated patients outweighed the delamanid drug costs. These results strongly support the application of Deltyba in treating MDR-TB patients.",2015-01-18331,25862597,Respir Med,Roland Diel,2015,109 / 5,632-41,No,25862597,"Roland Diel; Norbert Hittel; Tom Schaberg; Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba to background regimens in Germany, Respir Med, 2015 May; 109(5):0954-6111; 632-41",QALY,Germany,Not Stated,Not Stated,Adding delamanid (deltyba) to antibiotic regimen vs. Standard/Usual Care- Background regimen only,Not Stated,Not Stated,19 Years,"Female, Male",Full,10 Years,3.00,3.00,-3494.33,Euro,2013,-5156.02
14314,Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine,"INTRODUCTION: Opioid treatment for chronic pain is a known risk factor for falls and/or fractures in elderly patients. The latter cause a significant cost to the National Health Service and the Personal Social Services in the UK. Tramadol has a higher risk of fractures than some other opioid analgesics used to treat moderate-to-severe pain and, in the model described here, we investigate the cost effectiveness of transdermal buprenorphine treatment compared with tramadol in a high-risk population. METHODS: A model was developed to assess the cost effectiveness of tramadol compared with transdermal buprenorphine over a 1-year time horizon and a patient population of high-risk patients (female patients age 75 or older). To estimate the total cost and quality-adjusted life years (QALYs) of treatment, published odds ratios are used in combination with the published incidence rates of four types of fracture: hip, wrist, humerus and other. RESULTS: The model shows tramadol to be associated with 1,058 more fractures per 100,000 patients per year compared with transdermal buprenorphine, resulting in transdermal buprenorphine being cost-effective with an incremental cost-effectiveness ratio of less than pound7,000 compared with tramadol. Sensitivity analysis found this result to be robust. LIMITATIONS: In the UK data, there is uncertainty regarding the transdermal buprenorphine odds ratios for fractures. Odds ratios published in Danish and Swedish studies show similar point estimates but are associated with less uncertainty. CONCLUSION: Transdermal buprenorphine is cost-effective compared to tramadol at a willingness-to-pay threshold of pound20,000 per QALY.",2015-01-18334,25861916,Eur J Health Econ,Alexander Hirst,2015,/,,Yes,25861916,"Alexander Hirst; Chris Knight; Matt Hirst; Will Dunlop; Ron Akehurst; Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine, Eur J Health Econ, 2015 Sep 10; ():1618-7598",QALY,United Kingdom,Not Stated,Not Stated,Tramadol vs. Transdermal buprenorphine,High fracture risk,Not Stated,75 Years,Female,Full,1 Year,Not Stated,Not Stated,6979,United Kingdom,2014,12577.19
14315,Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly,"PURPOSE: This study aimed to evaluate the cost-effectiveness of statins for primary prevention of stroke and myocardial infarction (MI) in the elderly in Singapore. METHODS: A Markov model was developed to investigate the lifetime costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) of statin treatment in those aged 65 years and older without a history of stroke or MI from the perspective of Singapore's healthcare system, using elderly-specific clinical data and local costs from hospital databases. A lifetime horizon was used and all costs and health outcomes were discounted at 3% annually. RESULTS: In the base-case analysis, statin treatment prevented an additional four strokes and eight MIs among 1,000 ""healthy"" elderly individuals compared with no treatment. Statin treatment resulted in a QALY gain of 0.26 and additional costs of SGD 11,314 per person, yielding an ICER of SGD 43,925 (USD 33,495) per QALY gained. The results were sensitive to statin effectiveness, particularly statins' effect on all-cause mortality, and cost of statin medication. Probabilistic sensitivity analysis demonstrated that the probability of statin treatment being cost-effective was 72% at a willingness-to-pay threshold of SGD 65,000 (USD 49,546) per QALY gained. Shortening the time horizon from lifetime to 10 years (simulating limited life expectancy) considerably increased the ICER to SGD 291,313 (USD 167,171) per QALY. Female gender and younger age were also associated with higher ICERs owing to a lower baseline risk of cardiovascular disease (CVD) and higher costs to manage events in these subgroups. CONCLUSIONS: Statin treatment for the primary prevention of CVD in the elderly was cost-effective. However, treatment warrants re-evaluation when the prognosis of the individual is considered less than ten years; other goals may take precedence over CVD prevention.",2015-01-18335,25860556,Cardiovasc Drugs Ther,Liang Lin,2015,29 / 2,187-97,No,25860556,"Liang Lin; Monica Teng; Ying Jiao Zhao; Ai Leng Khoo; Raymond Chee Seong Seet; Quek Wei Yong; Tiong Cheng Yeo; Boon Peng Lim; Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly, Cardiovasc Drugs Ther, 2015 Apr; 29(2):0920-3206; 187-97",QALY,Singapore,Not Stated,Not Stated,Statin treatment vs. None,Not Stated,85 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,43925,Singapore,2013,39012.15
14316,Endovascular strategy or open repair for ruptured abdominal aortic aneurysm: one-year outcomes from the IMPROVE randomized trial,"AIMS: To report the longer term outcomes following either a strategy of endovascular repair first or open repair of ruptured abdominal aortic aneurysm, which are necessary for both patient and clinical decision-making. METHODS AND RESULTS: This pragmatic multicentre (29 UK and 1 Canada) trial randomized 613 patients with a clinical diagnosis of ruptured aneurysm; 316 to an endovascular first strategy (if aortic morphology is suitable, open repair if not) and 297 to open repair. The principal 1-year outcome was mortality; secondary outcomes were re-interventions, hospital discharge, health-related quality-of-life (QoL) (EQ-5D), costs, Quality-Adjusted-Life-Years (QALYs), and cost-effectiveness [incremental net benefit (INB)]. At 1 year, all-cause mortality was 41.1% for the endovascular strategy group and 45.1% for the open repair group, odds ratio 0.85 [95% confidence interval (CI) 0.62, 1.17], P = 0.325, with similar re-intervention rates in each group. The endovascular strategy group and open repair groups had average total hospital stays of 17 and 26 days, respectively, P < 0.001. Patients surviving rupture had higher average EQ-5D utility scores in the endovascular strategy vs. open repair groups, mean differences 0.087 (95% CI 0.017, 0.158), 0.068 (95% CI -0.004, 0.140) at 3 and 12 months, respectively. There were indications that QALYs were higher and costs lower for the endovascular first strategy, combining to give an INB of pound3877 (95% CI pound253, pound7408) or euro4356 (95% CI euro284, euro8323). CONCLUSION: An endovascular first strategy for management of ruptured aneurysms does not offer a survival benefit over 1 year but offers patients faster discharge with better QoL and is cost-effective. CLINICAL TRIAL REGISTRATION: ISRCTN 48334791.",2015-01-18343,25855369,Eur Heart J,IMPROVE Trial Investigators,2015,36 / 31,2061-2069,No,25855369,"IMPROVE Trial Investigators; Endovascular strategy or open repair for ruptured abdominal aortic aneurysm: one-year outcomes from the IMPROVE randomized trial, Eur Heart J, 2015 Aug 14; 36(31):0195-668X; 2061-2069",QALY,United Kingdom,Not Stated,Not Stated,Endovascular strategy vs. Standard/Usual Care- open repair,Not Stated,Not Stated,50 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,-44788.46,United Kingdom,2012,-80039.88
14317,Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway,"BACKGROUND: Lixisenatide is a potent, selective and short-acting once daily prandial glucagon-like peptide-1 receptor agonist which lowers glycohemoglobin and body weight by clinically significant amounts in patients with type 2 diabetes treated with basal insulin, with limited risk of hypoglycemia. OBJECTIVE: To assess the cost-effectiveness of lixisenatide versus bolus insulin, both in combination with basal insulin, in patients with type 2 diabetes in Norway. METHODS: The IMS CORE Diabetes Model, a non-product-specific and validated simulation model, was used to make clinical and cost projections. Transition probabilities, risk adjustments and the progression of complication risk factors were derived from the UK Prospective Diabetes Study, supplemented with Norwegian data. Patients were assumed to receive combination treatment with basal insulin, lixisenatide or bolus insulin therapy for 3 years, followed by intensification of a basal-bolus insulin regimen for their remaining lifetime. Simulated healthcare costs, taken from the public payer perspective, were derived from microcosting and diagnosis related groups, discounted at 4% per annum and reported in Norwegian krone (NOK). Productivity costs were also captured based on extractions from the Norwegian Labor and Welfare Administration. Health state utilities were derived from a systematic literature review. Sensitivity and scenario analyses were performed. RESULTS: Lixisenatide in combination with basal insulin was associated with increased quality-adjusted life years (QALYs) and reduced lifetime healthcare costs compared to bolus insulin in combination with basal insulin in patients with Type 2 diabetes, and can be considered dominant. The net monetary benefit of lixisenatide versus bolus insulin was NOK 39,369 per patient. Results were sensitive to discounting, the application of excess body weight associated disutility and uncertainty surrounding the changes in HbA1c. CONCLUSIONS: Lixisenatide may be considered an economically efficient therapy in combination with basal insulin in the Norwegian setting, due to cost savings, weight loss and associated gains in health-related quality of life.",2015-01-18349,25853868,Eur J Public Health,Pernilla Huetson,2015,/,1-13,No,25853868,"Pernilla Huetson; James L Palmer; Andree Levorsen; Marie Fournier; Maeva Germe; Euan McLeod; Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway, Eur J Public Health, 2015 Sep 21; ():1464-360X; 1-13",QALY,Norway,Not Stated,Not Stated,Once daily glucagon-like peptide 1 (glp-1) receptor agonist lixisenatide with basal insulin vs. Bolus insulin with basal insulin,Not Stated,Not Stated,19 Years,"Female, Male",Full,"45 Years, 20 years",4.00,4.00,-104075.76,Norway,2012,-20178.45
14318,Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany,"We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban's ENGAGE-AF, dabigatran's RE-LY, rivaroxaban's ROCKET, and apixaban's ARISTOTLE trials. The base-case analyses of a 65-year-old person with a CHADS2 score >1 gained 0.17 and 0.21 quality-adjusted life years over warfarin for 30 mg od and 60 mg od edoxaban, respectively. The incremental cost-effectiveness ratio was 50.000 and 68.000 euro per quality-adjusted life years for the higher and lower dose of edoxaban (Monte Carlo simulation). These findings were also similar to those for apixaban and more cost-effective than the other NOAC regimens. The current market costs for direct oral anticoagulants are high in relation to the quality of life gained from a German public health care insurance perspective. The willingness-to-pay threshold was lowest for 60 mg edoxaban compared to all direct oral anticoagulants and for 30 mg edoxaban compared to dabigatran and rivaroxaban.",2015-01-18350,25853142,J Skin Cancer,Martin Krejczy,2015,2015 /,876923,No,25853142,"Martin Krejczy; Job Harenberg; Martin Wehling; Konrad Obermann; Gregory Y H Lip; Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany, J Skin Cancer, 2015; 2015():2090-2905; 876923",QALY,Germany,Not Stated,Not Stated,Edoxaban 30 mg once daily vs. Standard/Usual Care- Warfarin,Increased risk for stroke (CHADS2-score >1) with no contraindications to anticoagulation,65 Years,65 Years,"Female, Male",Full,20 Years,5.00,5.00,68275,Euro,2012,98965.17
14319,Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany,"We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban's ENGAGE-AF, dabigatran's RE-LY, rivaroxaban's ROCKET, and apixaban's ARISTOTLE trials. The base-case analyses of a 65-year-old person with a CHADS2 score >1 gained 0.17 and 0.21 quality-adjusted life years over warfarin for 30 mg od and 60 mg od edoxaban, respectively. The incremental cost-effectiveness ratio was 50.000 and 68.000 euro per quality-adjusted life years for the higher and lower dose of edoxaban (Monte Carlo simulation). These findings were also similar to those for apixaban and more cost-effective than the other NOAC regimens. The current market costs for direct oral anticoagulants are high in relation to the quality of life gained from a German public health care insurance perspective. The willingness-to-pay threshold was lowest for 60 mg edoxaban compared to all direct oral anticoagulants and for 30 mg edoxaban compared to dabigatran and rivaroxaban.",2015-01-18350,25853142,J Skin Cancer,Martin Krejczy,2015,2015 /,876923,No,25853142,"Martin Krejczy; Job Harenberg; Martin Wehling; Konrad Obermann; Gregory Y H Lip; Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany, J Skin Cancer, 2015; 2015():2090-2905; 876923",QALY,Germany,Not Stated,Not Stated,Edoxaban 60 mg once daily vs. Standard/Usual Care- Warfarin,Increased risk for stroke (CHADS2-score >1) with no contraindications to anticoagulation,65 Years,65 Years,"Female, Male",Full,20 Years,5.00,5.00,50411,Euro,2012,73071.15
14320,Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany,"We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban's ENGAGE-AF, dabigatran's RE-LY, rivaroxaban's ROCKET, and apixaban's ARISTOTLE trials. The base-case analyses of a 65-year-old person with a CHADS2 score >1 gained 0.17 and 0.21 quality-adjusted life years over warfarin for 30 mg od and 60 mg od edoxaban, respectively. The incremental cost-effectiveness ratio was 50.000 and 68.000 euro per quality-adjusted life years for the higher and lower dose of edoxaban (Monte Carlo simulation). These findings were also similar to those for apixaban and more cost-effective than the other NOAC regimens. The current market costs for direct oral anticoagulants are high in relation to the quality of life gained from a German public health care insurance perspective. The willingness-to-pay threshold was lowest for 60 mg edoxaban compared to all direct oral anticoagulants and for 30 mg edoxaban compared to dabigatran and rivaroxaban.",2015-01-18350,25853142,J Skin Cancer,Martin Krejczy,2015,2015 /,876923,No,25853142,"Martin Krejczy; Job Harenberg; Martin Wehling; Konrad Obermann; Gregory Y H Lip; Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany, J Skin Cancer, 2015; 2015():2090-2905; 876923",QALY,Germany,Not Stated,Not Stated,Dabigatran 110 mg twice daily vs. Standard/Usual Care- Warfarin,Increased risk for stroke (CHADS2-score >1) with no contraindications to anticoagulation,65 Years,65 Years,"Female, Male",Full,20 Years,5.00,5.00,294349,Euro,2012,426661.26
14321,Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany,"We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban's ENGAGE-AF, dabigatran's RE-LY, rivaroxaban's ROCKET, and apixaban's ARISTOTLE trials. The base-case analyses of a 65-year-old person with a CHADS2 score >1 gained 0.17 and 0.21 quality-adjusted life years over warfarin for 30 mg od and 60 mg od edoxaban, respectively. The incremental cost-effectiveness ratio was 50.000 and 68.000 euro per quality-adjusted life years for the higher and lower dose of edoxaban (Monte Carlo simulation). These findings were also similar to those for apixaban and more cost-effective than the other NOAC regimens. The current market costs for direct oral anticoagulants are high in relation to the quality of life gained from a German public health care insurance perspective. The willingness-to-pay threshold was lowest for 60 mg edoxaban compared to all direct oral anticoagulants and for 30 mg edoxaban compared to dabigatran and rivaroxaban.",2015-01-18350,25853142,J Skin Cancer,Martin Krejczy,2015,2015 /,876923,No,25853142,"Martin Krejczy; Job Harenberg; Martin Wehling; Konrad Obermann; Gregory Y H Lip; Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany, J Skin Cancer, 2015; 2015():2090-2905; 876923",QALY,Germany,Not Stated,Not Stated,Dabigatran 150 mg twice daily vs. Standard/Usual Care- Warfarin,Increased risk for stroke (CHADS2-score >1) with no contraindications to anticoagulation,65 Years,65 Years,"Female, Male",Full,20 Years,5.00,5.00,163184,Euro,2012,236536.53
14322,Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany,"We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban's ENGAGE-AF, dabigatran's RE-LY, rivaroxaban's ROCKET, and apixaban's ARISTOTLE trials. The base-case analyses of a 65-year-old person with a CHADS2 score >1 gained 0.17 and 0.21 quality-adjusted life years over warfarin for 30 mg od and 60 mg od edoxaban, respectively. The incremental cost-effectiveness ratio was 50.000 and 68.000 euro per quality-adjusted life years for the higher and lower dose of edoxaban (Monte Carlo simulation). These findings were also similar to those for apixaban and more cost-effective than the other NOAC regimens. The current market costs for direct oral anticoagulants are high in relation to the quality of life gained from a German public health care insurance perspective. The willingness-to-pay threshold was lowest for 60 mg edoxaban compared to all direct oral anticoagulants and for 30 mg edoxaban compared to dabigatran and rivaroxaban.",2015-01-18350,25853142,J Skin Cancer,Martin Krejczy,2015,2015 /,876923,No,25853142,"Martin Krejczy; Job Harenberg; Martin Wehling; Konrad Obermann; Gregory Y H Lip; Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany, J Skin Cancer, 2015; 2015():2090-2905; 876923",QALY,Germany,Not Stated,Not Stated,Rivaroxaban 20 mg once daily vs. Standard/Usual Care- Warfarin,Increased risk for stroke (CHADS2-score >1) with no contraindications to anticoagulation,65 Years,65 Years,"Female, Male",Full,20 Years,5.00,5.00,133926,Euro,2012,194126.82
14323,Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany,"We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban's ENGAGE-AF, dabigatran's RE-LY, rivaroxaban's ROCKET, and apixaban's ARISTOTLE trials. The base-case analyses of a 65-year-old person with a CHADS2 score >1 gained 0.17 and 0.21 quality-adjusted life years over warfarin for 30 mg od and 60 mg od edoxaban, respectively. The incremental cost-effectiveness ratio was 50.000 and 68.000 euro per quality-adjusted life years for the higher and lower dose of edoxaban (Monte Carlo simulation). These findings were also similar to those for apixaban and more cost-effective than the other NOAC regimens. The current market costs for direct oral anticoagulants are high in relation to the quality of life gained from a German public health care insurance perspective. The willingness-to-pay threshold was lowest for 60 mg edoxaban compared to all direct oral anticoagulants and for 30 mg edoxaban compared to dabigatran and rivaroxaban.",2015-01-18350,25853142,J Skin Cancer,Martin Krejczy,2015,2015 /,876923,No,25853142,"Martin Krejczy; Job Harenberg; Martin Wehling; Konrad Obermann; Gregory Y H Lip; Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany, J Skin Cancer, 2015; 2015():2090-2905; 876923",QALY,Germany,Not Stated,Not Stated,Apixaban 5 mg twice daily vs. Standard/Usual Care- Warfarin,Increased risk for stroke (CHADS2-score >1) with no contraindications to anticoagulation,65 Years,65 Years,"Female, Male",Full,20 Years,5.00,5.00,57245,Euro,2012,82977.09
14324,An economic evaluation of conception strategies for heterosexual serodiscordant couples where the male partner is HIV-positive,"BACKGROUND: To conduct an economic evaluation of the three commonly used interventions that reduce sexual HIV transmission when an HIV-negative female aims to conceive with an HIV-positive male on combination antiretroviral therapy (condomless sex restricted to timed ovulation [CS], sperm washing with intrauterine insemination [SW] and condomless sex restricted to timed ovulation with pre-exposure prophylaxis [CS-PrEP]). As SW and CS-PrEP are only privately available for pregnancy planning for this population in Canada, this study was conducted to inform policy decisions concerning potential public health insurance coverage, as well as to inform fertility counselling in settings with adequate combination antiretroviral therapy access globally. METHODS: We developed a cohort Markov model with a lifetime horizon and used the perspective of Ontario's Ministry of Health (MOH). Input parameters were drawn from literature, the MOH's Schedule of Benefits and a time trade-off questionnaire designed for this study. Outcome measures included quality-adjusted life-years and incremental cost-effectiveness. Costs and benefits were discounted at annual rates of 3%. Costs were reported in Canadian 2013 dollars and an exchange rate of 1 USD to 1.066 CND was applied where necessary. Sensitivity analysis assessed the uncertainty of model parameters. RESULTS: The base case analysis found that CS-PrEP and SW were each more costly and less effective at conception than CS. The results were robust in the sensitivity analysis and suggest that CS is the dominant conception strategy in this population. CONCLUSIONS: Neither CS-PrEP nor SW represent better value for money relative to CS as a conception option for HIV-discordant couples with positive male partners. Based on these findings, CS-PrEP and SW cannot be recommended for public-funding in developed countries.",2015-01-18360,25849113,Antivir Ther,Michelle Letchumanan,2015,/,,No,25849113,"Michelle Letchumanan; Peter C Coyte; Mona Loutfy; An economic evaluation of conception strategies for heterosexual serodiscordant couples where the male partner is HIV-positive, Antivir Ther, 2015 Apr 7; ():1359-6535",QALY,Canada,Not Stated,Not Stated,"Condomless sex restricted to timed ovulation, with the administration of prep (pre-exposure prophylaxis) vs. CS - Condomless sex restricted to timed ovulation","Heterosexual serodiscordant couple with HIV-positive male partners, whose plasma viral load was undetectable on cART for at least 6 months, with 30-year-old HIV-negative female partner",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-2920,Canada,2013,-3150.74
14325,An economic evaluation of conception strategies for heterosexual serodiscordant couples where the male partner is HIV-positive,"BACKGROUND: To conduct an economic evaluation of the three commonly used interventions that reduce sexual HIV transmission when an HIV-negative female aims to conceive with an HIV-positive male on combination antiretroviral therapy (condomless sex restricted to timed ovulation [CS], sperm washing with intrauterine insemination [SW] and condomless sex restricted to timed ovulation with pre-exposure prophylaxis [CS-PrEP]). As SW and CS-PrEP are only privately available for pregnancy planning for this population in Canada, this study was conducted to inform policy decisions concerning potential public health insurance coverage, as well as to inform fertility counselling in settings with adequate combination antiretroviral therapy access globally. METHODS: We developed a cohort Markov model with a lifetime horizon and used the perspective of Ontario's Ministry of Health (MOH). Input parameters were drawn from literature, the MOH's Schedule of Benefits and a time trade-off questionnaire designed for this study. Outcome measures included quality-adjusted life-years and incremental cost-effectiveness. Costs and benefits were discounted at annual rates of 3%. Costs were reported in Canadian 2013 dollars and an exchange rate of 1 USD to 1.066 CND was applied where necessary. Sensitivity analysis assessed the uncertainty of model parameters. RESULTS: The base case analysis found that CS-PrEP and SW were each more costly and less effective at conception than CS. The results were robust in the sensitivity analysis and suggest that CS is the dominant conception strategy in this population. CONCLUSIONS: Neither CS-PrEP nor SW represent better value for money relative to CS as a conception option for HIV-discordant couples with positive male partners. Based on these findings, CS-PrEP and SW cannot be recommended for public-funding in developed countries.",2015-01-18360,25849113,Antivir Ther,Michelle Letchumanan,2015,/,,No,25849113,"Michelle Letchumanan; Peter C Coyte; Mona Loutfy; An economic evaluation of conception strategies for heterosexual serodiscordant couples where the male partner is HIV-positive, Antivir Ther, 2015 Apr 7; ():1359-6535",QALY,Canada,Not Stated,Not Stated,Sperm washing followed by intrauterine insemination (iui) vs. CS - Condomless sex restricted to timed ovulation,"Heterosexual serodiscordant couple with HIV-positive male partners, whose plasma viral load was undetectable on cART for at least 6 months, with 30-year-old HIV-negative female partner",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-46593.75,Canada,2013,-50275.68
14326,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + pegylated interferon 2a + ribavirin for 12 weeks vs. Telaprevir + pegylated interferon 2a + ribavirin,"Genotype 1 virus, treatment nave, interferon eligible",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,11836,United Kingdom,2012,21151.7
14327,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + pegylated interferon 2a + ribavirin for 12 weeks vs. Boceprevir + pegylated interferon 2b + ribavirin,"Genotype 1 virus, treatment nave, interferon eligible",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,7292,United Kingdom,2012,13031.28
14328,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + pegylated interferon 2a + ribavirin for 12 weeks vs. pegylated interferon 2a + ribavirin for 48 weeks,"Genotype 1 virus, treatment nave, interferon eligible",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,14930,United Kingdom,2012,26680.88
14329,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + ribavirin for 24 weeks vs. None,"Genotype 1 virus, treatment nave, unsuitable for interferon",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,49249,United Kingdom,2012,88011.16
14330,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + ribavirin for 12 weeks vs. Pegylated interferon 2a + ribavirinfor 24 weeks,"Genotype 2 virus, treatment nave, interferon eligible",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,46324,United Kingdom,2012,82783.99
14331,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + ribavirin for 12 weeks vs. None,"Genotype 2 virus, treatment nave, unsuitable for interferon",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,8154,United Kingdom,2012,14571.73
14332,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + ribavirin for 12 weeks vs. pegylated interferon 2a + ribavirin for 48 weeks,"Genotype 2 virus, treatment experienced, interferon eligible",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,14185,United Kingdom,2012,25349.51
14333,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + ribavirin for 12 weeks vs. None,"Genotype 2 virus, treatment experienced, interferon eligible",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,10126,United Kingdom,2012,18095.82
14334,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + ribavirin for 12 weeks vs. None,"Genotype 2 virus, treatment experienced, unsuitable for interferon",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,8591,United Kingdom,2012,15352.67
14335,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + pegylated interferon 2a + ribavirin for 12 weeks vs. Pegylated interferon 2a + ribavirin for 24 weeks,"Genotype 3 virus, treatment naive, interferon eligible",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,20613,United Kingdom,2012,36836.77
14336,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + ribavirin for 24 weeks vs. None,"Genotype 3 virus, treatment naive, unsuitable for interferon",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,21478,United Kingdom,2012,38382.58
14337,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + pegylated interferon 2a + ribavirin for 12 weeks vs. None,"Genotype 3 virus, treatment experienced, interferon eligible",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,8557,United Kingdom,2012,15291.91
14338,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + pegylated interferon 2a + ribavirin for 12 weeks vs. pegylated interferon 2a + ribavirin for 48 weeks,"Genotype 3 virus, treatment experienced, interferon eligible",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,12246,United Kingdom,2012,21884.4
14339,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + ribavirin for 12 weeks vs. None,"Genotype 3 virus, treatment experienced, unsuitable for interferon",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,28569,United Kingdom,2012,51054.66
14340,Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients,"The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first-generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir-based regimens have resulted in >90% sustained virological response across treatment-naive genotype 1-6 patients in five phase III clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost-effectiveness of sofosbuvir within the current licensed indication, for genotype 1-6 in the UK. A Markov model followed a cohort of 10 000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir-regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the UK. Sofosbuvir proved to be cost-effective in most patient populations with incremental cost-effectiveness ratios (ICERs) at pound11 836/QALY and pound7292/QALY against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted ICER of pound18 761/QALY. Sofosbuvir-based regimens are a cost-effective option for the majority of hepatitis C-infected patients in the United Kingdom although the incremental cost-effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.",2015-01-18363,25847572,Arh Hig Rada Toksikol,S Cure,2015,/,,No,25847572,"S Cure; I Guerra; G Dusheiko; Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients, Arh Hig Rada Toksikol, 2015 Jun 25; ():0004-1254",QALY,United Kingdom,Not Stated,Not Stated,Sofosbuvir + peglyated interferon 2a + ribavirin for 12 weeks vs. peglyated interferon 2a + ribavirin for 48 weeks,"Genotype 4/5/6 virus, treatment nave",64 Years,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,26797,United Kingdom,2012,47887.98
14341,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + stress echocardiography (echo) invasive diagnostic work-up (i) vs. None,low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,22000,United States,2011,25312.83
14342,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Stress echocardiography (echo) invasive diagnostic work-up vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14343,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + stress echocardiography (echo) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14344,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + cardiac magnetic resonance imaging (cmr) invasive diagnostic work-up vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14345,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + single-photon emmisson computed tomography (spect) invasive diagnostic work-up vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14346,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) invasive diagnostic work-up vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14347,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + cardiac magnetic resonance imaging (cmr) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14348,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + single-photon emmisson computed tomography (spect) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14349,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Cardiac magnetic resonance imaging (cmr) invasive diagnostic work-up vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14350,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Stress echocardiography (echo) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,-86600,United States,2011,-99640.49
14351,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Single-photon emmisson computed tomography (spect) invasive diagnostic work-up vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14352,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,-121400,United States,2011,-139680.78
14353,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Catheter-based coronary angiography (cag) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,-86000,United States,2011,-98950.14
14354,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Cardiac magnetic resonance imaging (cmr) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,-220900,United States,2011,-254163.8
14355,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Single-photon emmisson computed tomography (spect) vs. Cardiac Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i)magnetic resonance imaging (CMR),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,-334900,United States,2011,-385330.26
14356,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + stress echocardiography (echo) invasive diagnostic work-up (i) vs. None,low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,21000,United States,2011,24162.24
14357,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Stress echocardiography (echo) invasive diagnostic work-up (i) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14358,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + cardiac magnetic resonance imaging (cmr) invasive diagnostic work-up vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14359,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + single-photon emmisson computed tomography (spect) invasive diagnostic work-up (i) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14360,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + stress echocardiography (echo) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14361,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) invasive diagnostic work-up vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14362,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + cardiac magnetic resonance imaging (cmr) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14363,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Cardiac magnetic resonance imaging (cmr) invasive diagnostic work-up vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14364,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) + single-photon emmisson computed tomography (spect) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14365,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Single-photon emmisson computed tomography (spect) invasive diagnostic work-up (i) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14366,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Stress echocardiography (echo) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,Not Stated,United States,2011,Not Stated
14367,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Coronary computed tomography angiography (ccta) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,-135900,United States,2011,-156364.24
14368,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Catheter-based coronary angiography (cag) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,-186900,United States,2011,-215043.97
14369,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Cardiac magnetic resonance imaging (cmr) vs. Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,-244800,United States,2011,-281662.73
14370,The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis,"BACKGROUND: The optimal imaging strategy for patients with stable chest pain is uncertain. OBJECTIVE: To determine the cost-effectiveness of different imaging strategies for patients with stable chest pain. DESIGN: Microsimulation state-transition model. DATA SOURCES: Published literature. TARGET POPULATION: 60-year-old patients with a low to intermediate probability of coronary artery disease (CAD). TIME HORIZON: Lifetime. PERSPECTIVE: The United States, the United Kingdom, and the Netherlands. INTERVENTION: Coronary computed tomography (CT) angiography, cardiac stress magnetic resonance imaging, stress single-photon emission CT, and stress echocardiography. OUTCOME MEASURES: Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategy that maximized QALYs and was cost-effective in the United States and the Netherlands began with coronary CT angiography, continued with cardiac stress imaging if angiography found at least 50% stenosis in at least 1 coronary artery, and ended with catheter-based coronary angiography if stress imaging induced ischemia of any severity. For U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiography if coronary CT angiography found only moderate CAD or stress imaging induced only mild ischemia. In these strategies, stress echocardiography was consistently more effective and less expensive than other stress imaging tests. For U.K. women, the optimal strategy was stress echocardiography followed by catheter-based coronary angiography if echocardiography induced mild or moderate ischemia. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to changes in the probability of CAD and assumptions about false-positive results. LIMITATIONS: All cardiac stress imaging tests were assumed to be available. Exercise electrocardiography was included only in a sensitivity analysis. Differences in QALYs among strategies were small. CONCLUSION: Coronary CT angiography is a cost-effective triage test for 60-year-old patients who have nonacute chest pain and a low to intermediate probability of CAD. PRIMARY FUNDING SOURCE: Erasmus University Medical Center.",2015-01-18368,25844996,Ann Intern Med,Tessa S S Genders,2015,162 / 7,474-84,No,25844996,"Tessa S S Genders; Steffen E Petersen; Francesca Pugliese; Amardeep G Dastidar; Kirsten E Fleischmann; Koen Nieman; M G Myriam Hunink; The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis, Ann Intern Med, 2015 Apr 7; 162(7):1539-3704; 474-84",QALY,United States of America,Not Stated,Not Stated,Single-photon emmisson computed tomography (spect) vs. Cardiac Coronary computed tomography angiography (CCTA) + stress echocardiography (ECHO) invasive diagnostic work-up (i)magnetic resonance imaging (CMR),low to intermediate probability of coronary heart disease (CAD),60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,-184900,United States,2011,-212742.81
14371,Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation,"BACKGROUND: Prevention of sudden cardiac arrest (SCA) after removal of an infected implantable cardioverter-defibrillator (ICD) is a challenging clinical dilemma. The cost-effectiveness of the wearable cardioverter-defibrillator (WCD) in this setting remains uncertain. OBJECTIVE: The purpose of this study was to compare the cost-effectiveness of the WCD with discharge home, discharge to a skilled nursing facility, or inpatient monitoring for the prevention of SCA after infected ICD removal. METHODS: A decision model was developed to compare the cost-effectiveness of use of the WCD to several different strategies for patients who undergo ICD removal. One-way and 2-way sensitivity analyses were performed to account for uncertainties. RESULTS: In the base-case analysis, the incremental cost-effectiveness of the WCD strategy was $20,300 per life-year (LY) or $26,436 per quality-adjusted life-year (QALY) compared to discharge home without a WCD. Discharge to a skilled nursing facility and in-hospital monitoring resulted in higher costs and worse clinical outcomes. The incremental cost-effectiveness ratio was as low as $15,392/QALY if the WCD successfully terminated 95% of SCA events and exceeded the $50,000/QALY willingness-to-pay threshold if the efficacy was <69%.The WCD strategy remained cost-effective, assuming 5.6% 2-month SCA risk, as long as the time to reimplantation was at least 2 weeks. CONCLUSION: The WCD likely is cost-effective in protecting patients against SCA after infected ICD removal while waiting for ICD reimplantation compared to keeping patients in the hospital or discharging them home or to a skilled nursing facility.",2015-01-18375,25839113,Heart Rhythm,Christopher A Healy,2015,12 / 7,1565-73,No,25839113,"Christopher A Healy; Roger G Carrillo; Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation, Heart Rhythm, 2015 Jul; 12(7):1556-3871; 1565-73",QALY,United States of America,Not Stated,Not Stated,Home with wearable vardioverter-defibrillator (WCD) until reimplantation vs. Home with no device until reimplantation,"Patients who undergo implantable cardioverter-difibrillator (ICD) extraction for an infectious indication, with a risk for sudden cardiac arrest (SCA) and immediate reimplantation of the device is not possible.",Not Stated,19 Years,Not Stated,Full,Lifetime,3.00,3.00,26436,United States,2014,28901.09
14372,Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation,"BACKGROUND: Prevention of sudden cardiac arrest (SCA) after removal of an infected implantable cardioverter-defibrillator (ICD) is a challenging clinical dilemma. The cost-effectiveness of the wearable cardioverter-defibrillator (WCD) in this setting remains uncertain. OBJECTIVE: The purpose of this study was to compare the cost-effectiveness of the WCD with discharge home, discharge to a skilled nursing facility, or inpatient monitoring for the prevention of SCA after infected ICD removal. METHODS: A decision model was developed to compare the cost-effectiveness of use of the WCD to several different strategies for patients who undergo ICD removal. One-way and 2-way sensitivity analyses were performed to account for uncertainties. RESULTS: In the base-case analysis, the incremental cost-effectiveness of the WCD strategy was $20,300 per life-year (LY) or $26,436 per quality-adjusted life-year (QALY) compared to discharge home without a WCD. Discharge to a skilled nursing facility and in-hospital monitoring resulted in higher costs and worse clinical outcomes. The incremental cost-effectiveness ratio was as low as $15,392/QALY if the WCD successfully terminated 95% of SCA events and exceeded the $50,000/QALY willingness-to-pay threshold if the efficacy was <69%.The WCD strategy remained cost-effective, assuming 5.6% 2-month SCA risk, as long as the time to reimplantation was at least 2 weeks. CONCLUSION: The WCD likely is cost-effective in protecting patients against SCA after infected ICD removal while waiting for ICD reimplantation compared to keeping patients in the hospital or discharging them home or to a skilled nursing facility.",2015-01-18375,25839113,Heart Rhythm,Christopher A Healy,2015,12 / 7,1565-73,No,25839113,"Christopher A Healy; Roger G Carrillo; Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation, Heart Rhythm, 2015 Jul; 12(7):1556-3871; 1565-73",QALY,United States of America,Not Stated,Not Stated,Skilled nursing facility (SNF) with no device until reimplantation vs. Home with wearable vardioverter-defibrillator (WCD) until reimplantation,"Patients who undergo implantable cardioverter-difibrillator (ICD) extraction for an infectious indication, with a risk for sudden cardiac arrest (SCA) and immediate reimplantation of the device is not possible.",Not Stated,19 Years,Not Stated,Full,Lifetime,3.00,3.00,-115189.66,United States,2014,-125930.78
14373,Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation,"BACKGROUND: Prevention of sudden cardiac arrest (SCA) after removal of an infected implantable cardioverter-defibrillator (ICD) is a challenging clinical dilemma. The cost-effectiveness of the wearable cardioverter-defibrillator (WCD) in this setting remains uncertain. OBJECTIVE: The purpose of this study was to compare the cost-effectiveness of the WCD with discharge home, discharge to a skilled nursing facility, or inpatient monitoring for the prevention of SCA after infected ICD removal. METHODS: A decision model was developed to compare the cost-effectiveness of use of the WCD to several different strategies for patients who undergo ICD removal. One-way and 2-way sensitivity analyses were performed to account for uncertainties. RESULTS: In the base-case analysis, the incremental cost-effectiveness of the WCD strategy was $20,300 per life-year (LY) or $26,436 per quality-adjusted life-year (QALY) compared to discharge home without a WCD. Discharge to a skilled nursing facility and in-hospital monitoring resulted in higher costs and worse clinical outcomes. The incremental cost-effectiveness ratio was as low as $15,392/QALY if the WCD successfully terminated 95% of SCA events and exceeded the $50,000/QALY willingness-to-pay threshold if the efficacy was <69%.The WCD strategy remained cost-effective, assuming 5.6% 2-month SCA risk, as long as the time to reimplantation was at least 2 weeks. CONCLUSION: The WCD likely is cost-effective in protecting patients against SCA after infected ICD removal while waiting for ICD reimplantation compared to keeping patients in the hospital or discharging them home or to a skilled nursing facility.",2015-01-18375,25839113,Heart Rhythm,Christopher A Healy,2015,12 / 7,1565-73,No,25839113,"Christopher A Healy; Roger G Carrillo; Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation, Heart Rhythm, 2015 Jul; 12(7):1556-3871; 1565-73",QALY,United States of America,Not Stated,Not Stated,Hospital telemetry unit until reimplantation vs. Home with wearable vardioverter-defibrillator (WCD) until reimplantation,"Patients who undergo implantable cardioverter-difibrillator (ICD) extraction for an infectious indication, with a risk for sudden cardiac arrest (SCA) and immediate reimplantation of the device is not possible",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-866700,United States,2014,-947517.46
14374,"Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms","OBJECTIVE: Open repair (OPEN) and conservative management (CONS) have been the treatments of choice for splenic artery aneurysms (SAAs) for many years. Endovascular repair (EV) has been increasingly used with good short-term results. In this study, we evaluated the cost-effectiveness of OPEN, EV, and CONS for the treatment of SAAs. METHODS: A decision analysis model was developed using TreeAge Pro 2013 software (TreeAge Inc, Williamstown, Mass) to evaluate the cost-effectiveness of the different treatments for SAAs. A hypothetical cohort of 10,000 55-year-old female patients with SAAs was assessed in the reference-case analysis. Perioperative mortality, disease-specific mortality rates, complications, rupture risks, and reinterventions were retrieved from a recent and extensive meta-analysis. Costs were analyzed with the 2014 Medicare database. The willingness to pay was set to $60,000/quality-adjusted life years (QALYs). Outcomes evaluated were QALYs, costs from the health care perspective, and the incremental cost-effectiveness ratio (ICER). Extensive sensitivity analyses were performed and different clinical scenarios evaluated. Probabilistic sensitivity analysis was performed to include the uncertainty around the variables. A flowchart for clinical decision-making was developed. RESULTS: For a 55-year-old female patient with a SAA, EV has the highest QALYs (11.32; 95% credibility interval [CI], 9.52-13.17), followed by OPEN (10.48; 95% CI, 8.75-12.25) and CONS (10.39; 95% CI, 8.96-11.87). The difference in effect for 55-year-old female patients between EV and OPEN is 0.84 QALY (95% CI, 0.42-1.34), comparable with 10 months in perfect health. EV is more effective and less costly than OPEN and more effective and more expensive compared with CONS, with an ICER of $17,154/QALY. Moreover, OPEN, with an ICER of $223,166/QALY, is not cost-effective compared with CONS. In elderly individuals (age >78 years), the ICER of EV vs CONS is $60,503/QALY and increases further with age, making EV no longer cost-effective. Very elderly patients (age >93 years) have higher QALYs and lower costs when treated with CONS. The EV group has the highest number of expected reinterventions, followed by CONS and OPEN, and the number of expected reinterventions decreases with age. CONCLUSIONS: EV is the most cost-effective treatment for most patient groups with SAAs, independent of the sex and risk profile of the patient. EV is superior to OPEN, being both cost-saving and more effective in all age groups. Elderly patients should be considered for CONS, based on the high costs in relation to the very small gain in health when treated with EV. The very elderly should be treated with CONS.",2015-01-18404,25827968,J Vasc Surg,Wouter Hogendoorn,2015,61 / 6,1432-40,No,25827968,"Wouter Hogendoorn; Anthi Lavida; M G Myriam Hunink; Frans L Moll; George Geroulakos; Bart E Muhs; Bauer E Sumpio; Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms, J Vasc Surg, 2015 Jun; 61(6):0741-5214; 1432-40",QALY,United States of America,Not Stated,Not Stated,Endovascular repair vs. Open repair,Not Stated,55 Years,55 Years,Female,Full,Lifetime,3.00,3.00,-4028.57,United States,2014,-4404.23
14375,"Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms","OBJECTIVE: Open repair (OPEN) and conservative management (CONS) have been the treatments of choice for splenic artery aneurysms (SAAs) for many years. Endovascular repair (EV) has been increasingly used with good short-term results. In this study, we evaluated the cost-effectiveness of OPEN, EV, and CONS for the treatment of SAAs. METHODS: A decision analysis model was developed using TreeAge Pro 2013 software (TreeAge Inc, Williamstown, Mass) to evaluate the cost-effectiveness of the different treatments for SAAs. A hypothetical cohort of 10,000 55-year-old female patients with SAAs was assessed in the reference-case analysis. Perioperative mortality, disease-specific mortality rates, complications, rupture risks, and reinterventions were retrieved from a recent and extensive meta-analysis. Costs were analyzed with the 2014 Medicare database. The willingness to pay was set to $60,000/quality-adjusted life years (QALYs). Outcomes evaluated were QALYs, costs from the health care perspective, and the incremental cost-effectiveness ratio (ICER). Extensive sensitivity analyses were performed and different clinical scenarios evaluated. Probabilistic sensitivity analysis was performed to include the uncertainty around the variables. A flowchart for clinical decision-making was developed. RESULTS: For a 55-year-old female patient with a SAA, EV has the highest QALYs (11.32; 95% credibility interval [CI], 9.52-13.17), followed by OPEN (10.48; 95% CI, 8.75-12.25) and CONS (10.39; 95% CI, 8.96-11.87). The difference in effect for 55-year-old female patients between EV and OPEN is 0.84 QALY (95% CI, 0.42-1.34), comparable with 10 months in perfect health. EV is more effective and less costly than OPEN and more effective and more expensive compared with CONS, with an ICER of $17,154/QALY. Moreover, OPEN, with an ICER of $223,166/QALY, is not cost-effective compared with CONS. In elderly individuals (age >78 years), the ICER of EV vs CONS is $60,503/QALY and increases further with age, making EV no longer cost-effective. Very elderly patients (age >93 years) have higher QALYs and lower costs when treated with CONS. The EV group has the highest number of expected reinterventions, followed by CONS and OPEN, and the number of expected reinterventions decreases with age. CONCLUSIONS: EV is the most cost-effective treatment for most patient groups with SAAs, independent of the sex and risk profile of the patient. EV is superior to OPEN, being both cost-saving and more effective in all age groups. Elderly patients should be considered for CONS, based on the high costs in relation to the very small gain in health when treated with EV. The very elderly should be treated with CONS.",2015-01-18404,25827968,J Vasc Surg,Wouter Hogendoorn,2015,61 / 6,1432-40,No,25827968,"Wouter Hogendoorn; Anthi Lavida; M G Myriam Hunink; Frans L Moll; George Geroulakos; Bart E Muhs; Bauer E Sumpio; Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms, J Vasc Surg, 2015 Jun; 61(6):0741-5214; 1432-40",QALY,United States of America,Not Stated,Not Stated,Endovascular repair vs. Conservative management,Not Stated,55 Years,55 Years,Female,Full,Lifetime,3.00,3.00,17154,United States,2014,18753.56
14376,"Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms","OBJECTIVE: Open repair (OPEN) and conservative management (CONS) have been the treatments of choice for splenic artery aneurysms (SAAs) for many years. Endovascular repair (EV) has been increasingly used with good short-term results. In this study, we evaluated the cost-effectiveness of OPEN, EV, and CONS for the treatment of SAAs. METHODS: A decision analysis model was developed using TreeAge Pro 2013 software (TreeAge Inc, Williamstown, Mass) to evaluate the cost-effectiveness of the different treatments for SAAs. A hypothetical cohort of 10,000 55-year-old female patients with SAAs was assessed in the reference-case analysis. Perioperative mortality, disease-specific mortality rates, complications, rupture risks, and reinterventions were retrieved from a recent and extensive meta-analysis. Costs were analyzed with the 2014 Medicare database. The willingness to pay was set to $60,000/quality-adjusted life years (QALYs). Outcomes evaluated were QALYs, costs from the health care perspective, and the incremental cost-effectiveness ratio (ICER). Extensive sensitivity analyses were performed and different clinical scenarios evaluated. Probabilistic sensitivity analysis was performed to include the uncertainty around the variables. A flowchart for clinical decision-making was developed. RESULTS: For a 55-year-old female patient with a SAA, EV has the highest QALYs (11.32; 95% credibility interval [CI], 9.52-13.17), followed by OPEN (10.48; 95% CI, 8.75-12.25) and CONS (10.39; 95% CI, 8.96-11.87). The difference in effect for 55-year-old female patients between EV and OPEN is 0.84 QALY (95% CI, 0.42-1.34), comparable with 10 months in perfect health. EV is more effective and less costly than OPEN and more effective and more expensive compared with CONS, with an ICER of $17,154/QALY. Moreover, OPEN, with an ICER of $223,166/QALY, is not cost-effective compared with CONS. In elderly individuals (age >78 years), the ICER of EV vs CONS is $60,503/QALY and increases further with age, making EV no longer cost-effective. Very elderly patients (age >93 years) have higher QALYs and lower costs when treated with CONS. The EV group has the highest number of expected reinterventions, followed by CONS and OPEN, and the number of expected reinterventions decreases with age. CONCLUSIONS: EV is the most cost-effective treatment for most patient groups with SAAs, independent of the sex and risk profile of the patient. EV is superior to OPEN, being both cost-saving and more effective in all age groups. Elderly patients should be considered for CONS, based on the high costs in relation to the very small gain in health when treated with EV. The very elderly should be treated with CONS.",2015-01-18404,25827968,J Vasc Surg,Wouter Hogendoorn,2015,61 / 6,1432-40,No,25827968,"Wouter Hogendoorn; Anthi Lavida; M G Myriam Hunink; Frans L Moll; George Geroulakos; Bart E Muhs; Bauer E Sumpio; Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms, J Vasc Surg, 2015 Jun; 61(6):0741-5214; 1432-40",QALY,United States of America,Not Stated,Not Stated,Open repair vs. Conservative management,Not Stated,55 Years,55 Years,Female,Full,Lifetime,3.00,3.00,223166,United States,2014,243975.63
14377,Cost-Effectiveness Analysis of Morcellation Hysterectomy for Myomas,"STUDY OBJECTIVE: To estimate the cost-effectiveness of eliminating morcellation in the surgical treatment of leiomyomas from a societal perspective. DESIGN: Cost-effectiveness analysis. DESIGN CLASSIFICATION: Not applicable. SETTING: A theoretical cohort of women undergoing hysterectomy for myoma disease large enough to require morcellation. PATIENTS: None. INTERVENTIONS: None. MEASUREMENTS: A decision analysis model was constructed using probabilities, costs, and utility data from published sources. A cost-effectiveness analysis analyzing both quality-adjusted life years (QALYs) and cases of disseminated cancer was performed to determine the incremental cost-effectiveness ratio (ICER) of eliminating morcellation as a tool in the surgical treatment of leiomyomas. Costs and utilities were discounted using standard methodology. The base case included health care system costs and costs incurred by the patient for surgery-related disability. One-way sensitivity analyses were performed to assess the effect of various assumptions. MAIN RESULTS: The cost to prevent 1 case of disseminated cancer was $10 540 832. A strategy of nonmorcellation hysterectomy via laparotomy costed more ($30 359.92 vs $20 853.15) and yielded more QALYs (21.284 vs 21.280) relative to morcellation hysterectomy. The ICER for nonmorcellation hysterectomy compared with morcellation hysterectomy was $2 184 172 per QALY. Health care costs (prolonged hospitalizations) and costs to patients of prolonged time away from work were the primary drivers of cost differential between the 2 strategies. Even when the incidence of occult sarcoma in leiomyoma surgery was ranged to twice that reported in the literature (.98%), the ICER for nonmorcellation hysterectomy was $644 393.30. CONCLUSIONS: Eliminating morcellation hysterectomy as a treatment for myomas is not cost-effective under a wide variety of probability and cost assumptions. Performing laparotomy for all patients who might otherwise be candidates for morcellation hysterectomy is a costly policy from a societal perspective.",2015-01-18407,25827327,J Minim Invasive Gynecol,Pietro Bortoletto,2015,22 / 5,820-6,No,25827327,"Pietro Bortoletto; Brett D Einerson; Emily S Miller; Magdy P Milad; Cost-Effectiveness Analysis of Morcellation Hysterectomy for Myomas, J Minim Invasive Gynecol, 2015 Jul-Aug; 22(5):1553-4669; 820-6",QALY,United States of America,Not Stated,Not Stated,Nonmorcellation hysterectomy via laparotomy vs. Morcellation hysterectomy via laparotomy,undergoing hysterectomy for myoma disease large enough to require morcellation,Not Stated,19 Years,Female,Full,Lifetime,3.00,3.00,2184172,United States,2013,2426575.46
14378,Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective,"BACKGROUND: Both the 2012 Beers list and the American Geriatric Society 'Choosing Wisely' campaign suggest restraint in the use of sedative-hypnotics for the treatment of insomnia in older people. Sedative hypnotic agents continue to be widely prescribed even though their use in the elderly is associated with an increased risk of falls, fractures, and emergency hospitalizations. OBJECTIVE: The aim of this study was to estimate the cost effectiveness of cognitive behavioral therapy (CBT) compared with sedative-hypnotics and no treatment for insomnia in the US Medicare population, adjusting for the risk of falls and related consequences. METHODS: A model-based economic evaluation (decision tree) using the US Medicare perspective and a conservative annual temporal framework was conducted. Simulations were performed in a hypothetical cohort of Medicare beneficiaries suffering from insomnia. The main outcome measure was the incremental cost per quality-adjusted life year (QALY) gained. Sensitivity analyses assessed the robustness of the base-case analysis. RESULTS: On an annual basis, CBT showed a dominance (cost: US$19,442; QALYs: 0.594) over sedative hypnotics (cost: US$32,452; QALYs: 0.552) and no treatment (cost: US$33,853; QALYs: 0.517). Assuming a willingness to pay of US$50,000, the net monetary benefit was positive for CBT (US$10,287) and negative for sedative hypnotics (-US$4,851) and no treatment (-US$7,993). CBT had a 95% chance of being the dominant strategy, with results most sensitive to an older adult's baseline risk of falling. CONCLUSION: Failure to consider drug harms such as drug-induced falls and hospitalization represents a growing public health concern, significantly underestimating the cost of sedative-hypnotic therapy and loss in quality of life for the elderly. Public payers should reconsider reimbursement of sedative-hypnotic drugs as first-line treatment for insomnia in older adults.",2015-01-18413,25825121,Drugs Aging,Cara Tannenbaum,2015,32 / 4,305-14,No,25825121,"Cara Tannenbaum; Vakaramoko Diaby; Dharmender Singh; Sylvie Perreault; Mireille Luc; Helen-Maria Vasiliadis; Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective, Drugs Aging, 2015 Apr; 32(4):1170-229X; 305-14",QALY,United States of America,Not Stated,Not Stated,"Cognitive behavioral therapy when fall-related consequences were considered vs. Sedative-hyonotic, zolpidem tartrate 5 mg every night at bedtime, for insomnia",more likely to experience insomnia; drug-induced falls,Not Stated,65 Years,"Female, Male",Full,"1 Year, 5 years",Not Stated,Not Stated,-309761.91,United States,2013,-344139.86
14379,Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective,"BACKGROUND: Both the 2012 Beers list and the American Geriatric Society 'Choosing Wisely' campaign suggest restraint in the use of sedative-hypnotics for the treatment of insomnia in older people. Sedative hypnotic agents continue to be widely prescribed even though their use in the elderly is associated with an increased risk of falls, fractures, and emergency hospitalizations. OBJECTIVE: The aim of this study was to estimate the cost effectiveness of cognitive behavioral therapy (CBT) compared with sedative-hypnotics and no treatment for insomnia in the US Medicare population, adjusting for the risk of falls and related consequences. METHODS: A model-based economic evaluation (decision tree) using the US Medicare perspective and a conservative annual temporal framework was conducted. Simulations were performed in a hypothetical cohort of Medicare beneficiaries suffering from insomnia. The main outcome measure was the incremental cost per quality-adjusted life year (QALY) gained. Sensitivity analyses assessed the robustness of the base-case analysis. RESULTS: On an annual basis, CBT showed a dominance (cost: US$19,442; QALYs: 0.594) over sedative hypnotics (cost: US$32,452; QALYs: 0.552) and no treatment (cost: US$33,853; QALYs: 0.517). Assuming a willingness to pay of US$50,000, the net monetary benefit was positive for CBT (US$10,287) and negative for sedative hypnotics (-US$4,851) and no treatment (-US$7,993). CBT had a 95% chance of being the dominant strategy, with results most sensitive to an older adult's baseline risk of falling. CONCLUSION: Failure to consider drug harms such as drug-induced falls and hospitalization represents a growing public health concern, significantly underestimating the cost of sedative-hypnotic therapy and loss in quality of life for the elderly. Public payers should reconsider reimbursement of sedative-hypnotic drugs as first-line treatment for insomnia in older adults.",2015-01-18413,25825121,Drugs Aging,Cara Tannenbaum,2015,32 / 4,305-14,No,25825121,"Cara Tannenbaum; Vakaramoko Diaby; Dharmender Singh; Sylvie Perreault; Mireille Luc; Helen-Maria Vasiliadis; Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective, Drugs Aging, 2015 Apr; 32(4):1170-229X; 305-14",QALY,United States of America,Not Stated,Not Stated,Cognitive behavioral therapy when fall-related consequences were considered vs. None,more likely to experience insomnia; drug-induced falls,Not Stated,65 Years,"Female, Male",Full,"1 Year, 5 years",Not Stated,Not Stated,-187155.84,United States,2013,-207926.75
14380,Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission,"PURPOSE: Surveillance imaging of asymptomatic patients with diffuse large B-cell lymphoma (DLBCL) in first remission remains controversial. A decision-analytic Markov model was developed to evaluate the cost-effectiveness of follow-up strategies following first-line immunochemotherapy. PATIENTS AND METHODS: Three strategies were compared in 55-year-old patient cohorts: routine clinical follow-up without serial imaging, routine follow-up with biannual computed tomography (CT) scans for 2 years, or routine follow-up with biannual [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography (PET/CT) for 2 years. The baseline model favored imaging-based strategies by associating asymptomatic imaging-detected relapses with improved clinical outcomes. Lifetime costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated for each surveillance strategy. RESULTS: Surveillance strategies utilizing 2 years of routine CT or PET/CT scans were associated with minimal survival benefit when compared with clinical follow-up without routine imaging (life-years gained: CT, 0.03 years; PET/CT, 0.04 years). The benefit of imaging-based follow-up remained small after quality-of-life adjustments (CT, 0.020 QALYs; PET/CT, 0.025 QALYs). Costs associated with imaging-based surveillance strategies are considerable; ICERs for imaging strategies compared with clinical follow-up were $164,960/QALY (95% CI, $116,510 to $766,930/QALY) and $168,750/QALY (95% CI, $117,440 to 853,550/QALY) for CT and PET/CT, respectively. Model conclusions were robust and remained stable on one-way and probabilistic sensitivity analyses. CONCLUSION: Our cost-effectiveness analysis suggests surveillance imaging of asymptomatic DLBCL patients in remission offers little clinical benefit at substantial economic costs.",2015-01-18417,25823735,J Clin Oncol,Scott F Huntington,2015,33 / 13,1467-74,No,25823735,"Scott F Huntington; Jakub Svoboda; Jalpa A Doshi; Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission, J Clin Oncol, 2015 May 1; 33(13):0732-183X; 1467-74",QALY,United States of America,Not Stated,Not Stated,Routine follow-up with biannual computed tomography (CT) scans for 2 years vs. Routine clinical follow-up without serial imaging,asymptomatic patients with complete response following primary treatment for Large B-cell lymphoma (DLBCL),55 Years,55 Years,"Female, Male",Full,Lifetime,3.00,3.00,164960,United States,2013,183267.57
14381,Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission,"PURPOSE: Surveillance imaging of asymptomatic patients with diffuse large B-cell lymphoma (DLBCL) in first remission remains controversial. A decision-analytic Markov model was developed to evaluate the cost-effectiveness of follow-up strategies following first-line immunochemotherapy. PATIENTS AND METHODS: Three strategies were compared in 55-year-old patient cohorts: routine clinical follow-up without serial imaging, routine follow-up with biannual computed tomography (CT) scans for 2 years, or routine follow-up with biannual [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography (PET/CT) for 2 years. The baseline model favored imaging-based strategies by associating asymptomatic imaging-detected relapses with improved clinical outcomes. Lifetime costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated for each surveillance strategy. RESULTS: Surveillance strategies utilizing 2 years of routine CT or PET/CT scans were associated with minimal survival benefit when compared with clinical follow-up without routine imaging (life-years gained: CT, 0.03 years; PET/CT, 0.04 years). The benefit of imaging-based follow-up remained small after quality-of-life adjustments (CT, 0.020 QALYs; PET/CT, 0.025 QALYs). Costs associated with imaging-based surveillance strategies are considerable; ICERs for imaging strategies compared with clinical follow-up were $164,960/QALY (95% CI, $116,510 to $766,930/QALY) and $168,750/QALY (95% CI, $117,440 to 853,550/QALY) for CT and PET/CT, respectively. Model conclusions were robust and remained stable on one-way and probabilistic sensitivity analyses. CONCLUSION: Our cost-effectiveness analysis suggests surveillance imaging of asymptomatic DLBCL patients in remission offers little clinical benefit at substantial economic costs.",2015-01-18417,25823735,J Clin Oncol,Scott F Huntington,2015,33 / 13,1467-74,No,25823735,"Scott F Huntington; Jakub Svoboda; Jalpa A Doshi; Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission, J Clin Oncol, 2015 May 1; 33(13):0732-183X; 1467-74",QALY,United States of America,Not Stated,Not Stated,Routine follow-up with biannual [18F]-fluorodeoxyglucose positron emission tomography computed tomography (PET/CT) vs. Routine clinical follow-up without serial imaging,asymptomatic patients with complete response following primary treatment for Large B-cell lymphoma (DLBCL),55 Years,55 Years,"Female, Male",Full,Lifetime,3.00,3.00,168750,United States,2013,187478.19
14382,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,Pegylated interferon-ribavirin 24 week vs. None,Treatment-nave noncirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,4800,United States,2013,5332.71
14383,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,Sofosbuvi-ribavirin for 12 weeks vs. Pegylated interferon-ribavirin 24 week,Treatment-nave noncirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-470000,United States,2013,-522161.47
14384,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of pegylated interferon-ribavirin-sofosbuvir vs. Pegylated interferon-ribavirin 24 weeks,Treatment-nave noncirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,263000,United States,2013,292188.23
14385,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,24 weeks of sofosbuvir-ribavirin vs. 12 weeks of pegylated interferon-ribavirin-sofosbuvir,Treatment-nave noncirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,266000,United States,2013,295521.17
14386,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of pegylated interferon-ribavirin-sofosbuvir vs. None,Treatment-experienced noncirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,82000,United States,2013,91100.51
14387,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of sofosbuvir-ribavirin vs. 12 weeks of pegylated interferon-ribavirin-sofosbuvir,Treatment-experienced noncirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-8571.43,United States,2013,-9522.7
14388,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,16 weeks of sofosbuvir-ribavirin vs. 12 weeks of pegylated interferon-ribavirin-sofosbuvir,Treatment-experienced noncirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-67500,United States,2013,-74991.28
14389,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,24 weeks of sofosbuvir-ribavirin vs. None,Treatment-experienced noncirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,820000,United States,2013,911005.12
14390,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,24 weeks of pegylated interferonribavirin vs. None,Treatment-naive cirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,13600,United States,2013,15109.35
14391,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of sofosbuvir-ribavirin vs. 24 weeks of pegylated interferon-ribavirin,Treatment-naive cirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,186000,United States,2013,206642.63
14392,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of pegylated interferon-ribavirin-sofosbuvir vs. 24 weeks of pegylated interferon-ribavirin,Treatment-naive cirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,22600,United States,2013,25108.19
14393,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,24 weeks of ribavirin-sofosbuvir vs. 12 weeks of pegylated interferon-ribavirin-sofosbuvir,Treatment-naive cirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,107000,United States,2013,118875.06
14394,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of ribavirin-sofosbuvir vs. None,Treatment-naive cirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,74117.65,United States,2013,82343.36
14395,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of pegylated interferon-ribavirin-sofosbuvir vs. None,Treatment-naive cirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,22300,United States,2013,24774.9
14396,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,16 weeks of ribavirin-sofosbuvir vs. None,Treatment-naive cirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-3913.04,United States,2013,-4347.32
14397,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,24 weeks of ribavirin-sofosbuvir vs. None,Treatment-naive cirrhotic patients with genotype 3 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-30454.54,United States,2013,-33834.45
14398,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,24 weeks of pegylated interferon-ribavirin vs. None,Treatment-naive noncirrhotic patients with genotype 2 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,2500,United States,2013,2777.45
14399,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of sofosbuvir-ribavirin vs. 24 weeks of pegylated interferon-ribavirin,Treatment-naive noncirrhotic patients with genotype 2 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,293333.31,United States,2013,325887.99
14400,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of sofosbuvir-ribavirin vs. None,Treatment-experienced noncirrhotic patients with genotype 2 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,63700,United States,2013,70769.54
